| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Microhelenin C targets cancer cells, particularly leukemic cells, with significant antileukemic activity. As a sesquiterpene lactone, it exhibits antitumor activity. The compound also has potential cytotoxic, antimicrobial, and antifungal properties. Its unique polyoxygenated structure may contribute to its interactions with cellular targets involved in cell proliferation and survival. Further research is needed to identify its specific molecular targets.
|
|---|---|
| ln Vitro |
Microhelenin C demonstrates significant antileukemic activity in vitro. The compound exhibits antitumor activity against various cancer cell lines. It has potential cytotoxic, antimicrobial, and antifungal properties. These in vitro findings support its potential applications in cancer research, particularly leukemia research, and natural product drug discovery.
|
| ln Vivo |
In vivo studies of Microhelenin C are limited as the compound is primarily used as a research chemical. Its significant antileukemic and antitumor activities suggest potential for in vivo evaluation in animal models of leukemia and other cancers. However, comprehensive in vivo pharmacological studies specifically targeting Microhelenin C are not well documented. The compound is intended for research use only and is not for human therapeutic use.
|
| Enzyme Assay |
In vitro cytotoxicity assays for Microhelenin C typically involve testing its activity against leukemia and other cancer cell lines. Cells are treated with varying concentrations of the compound and cell viability is assessed using MTT or similar colorimetric assays. IC50 values are determined from dose-response curves. Antimicrobial and antifungal activities are assessed using standard disc diffusion or broth microdilution methods. The compound's purity and identity are confirmed using analytical chemistry methods such as nuclear magnetic resonance spectroscopy, high-performance liquid chromatography, and mass spectrometry.
|
| Cell Assay |
In vitro cell-based assays for Microhelenin C involve culturing leukemia and other cancer cell lines to evaluate its antitumor activity. Cells are treated with varying concentrations of the compound and cell viability is assessed using MTT or similar colorimetric assays. Apoptosis is quantified using flow cytometry with Annexin V/PI staining or via caspase activity measurements. For antimicrobial studies, bacterial or fungal cultures are treated and cell viability is monitored. All experiments are performed with appropriate controls.
|
| Animal Protocol |
In vivo animal experiments for Microhelenin C would be conducted to evaluate its antileukemic and antitumor activities. Tumor-bearing animals (typically mice with leukemia xenografts) would be treated with the compound and tumor growth monitored. Parameters assessed would include tumor volume, survival, body weight, and general health. At study termination, tumors would be collected for histopathological examination. Control groups receiving vehicle alone would be included for comparison. All procedures would comply with institutional animal care and use committee guidelines.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Microhelenin C reflect its nature as a sesquiterpene lactone. It has a molecular weight of 346.42 and the molecular formula C20H26O5. The compound is stored as a powder at -20°C for up to 3 years. As a lipophilic sesquiterpene lactone, it would be absorbed through the gastrointestinal tract and distributed throughout the body. Complete pharmacokinetic profiling including half-life, clearance, volume of distribution, and bioavailability would require further systematic studies using appropriate analytical methods.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Microhelenin C has been evaluated in the context of its use as a research chemical. As a sesquiterpene lactone with cytotoxic and antimicrobial properties, it should be handled with caution. The compound has not been fully validated for medical applications. Proper handling procedures including use of personal protective equipment are recommended when working with the compound. The compound is not approved for human therapeutic use and is intended for research purposes only.
|
| References | |
| Additional Infomation |
Microhelenin C is a sesquiterpene lactone. It has been reported to exist in Calendula officinalis, Calendula tangutica, and Arnica stolonifera, and relevant data are available for reference.
Microhelenin C (CAS# 63569-07-3) has the molecular formula C20H26O5 and a molecular weight of 346.42. The compound is a sesquiterpene lactone isolated from Helenium microcephalum. Microhelenin C has significant antileukemic and antitumor activity. It features a unique polyoxygenated structure with potential cytotoxic, antimicrobial, and antifungal properties. |
| Molecular Formula |
C20H26O5
|
|---|---|
| Molecular Weight |
346.42
|
| Exact Mass |
346.178
|
| CAS # |
63569-07-3
|
| PubChem CID |
5281483
|
| Appearance |
Off-white to light yellow solid
|
| LogP |
2.843
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
25
|
| Complexity |
676
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
O1C([C@@]([H])(C([H])([H])[H])[C@]2([H])[C@@]1([H])C([H])([H])[C@@]([H])(C([H])([H])[H])[C@]1([H])C([H])=C([H])C([C@@]1(C([H])([H])[H])[C@@]2([H])OC(/C(=C(\[H])/C([H])([H])[H])/C([H])([H])[H])=O)=O)=O
|
| InChi Key |
KUPPZVXLWANEJJ-YFVRYKHXSA-N
|
| InChi Code |
InChI=1S/C20H26O5/c1-6-10(2)18(22)25-17-16-12(4)19(23)24-14(16)9-11(3)13-7-8-15(21)20(13,17)5/h6-8,11-14,16-17H,9H2,1-5H3/b10-6+/t11-,12+,13+,14-,16-,17+,20+/m1/s1
|
| Chemical Name |
[(1S,3aR,5R,5aR,8aR,9S,9aR)-1,5,8a-trimethyl-2,8-dioxo-3a,4,5,5a,9,9a-hexahydro-1H-azuleno[6,5-b]furan-9-yl] (E)-2-methylbut-2-enoate
|
| Synonyms |
Microhelenin C
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (288.67 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.22 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.22 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8867 mL | 14.4333 mL | 28.8667 mL | |
| 5 mM | 0.5773 mL | 2.8867 mL | 5.7733 mL | |
| 10 mM | 0.2887 mL | 1.4433 mL | 2.8867 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
